ArticlePloS one2025
Quzhuo tongbi formula for reducing gout flare related to uric acid lowering treatment: Study protocol for a multiple-center, randomized, double-blind, placebo, parallel-controlled clinical trial.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiota and uric acid excretion signaling in pathogenesis of hyperuricemia and acute gouty arthritis.iScience · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGout, a prevalent metabolic rheumatic disease, arises from the accumulation of monosodium urate (MSU) crystals in joints, directly associated with hyperuricemia. Long-term or lifelong urate-lowering therapy (ULT) stands as the primary management strategy. However, there is a significant risk of gout flares during ULT, and current methods have drawbacks, including side effects. Previous research has suggested a potential benefit of the Qu-zhuo Tong-bi formula (QTF) in the treatment and prevention of gout. This study aims to evaluate the effectiveness and safety of QTF in reducing gout flares during ULT.
methodThis is a multi-center, randomized, double-blind, placebo, parallel-controlled clinical trial conducted in four hospitals in Zhejiang Province, China. A total of 144 patients, aged 18-80 years, will be randomly allocated to either the intervention group (QTF + febuxostat) or the control group (placebo + febuxostat) for a 12-week treatment period. The primary outcome measure is the frequency of gout flares. Secondary outcome measures include the time from the patient's enrollment to the first occurrence of gout flare (in days), duration of gout flare (in days), health assessment questionnaire disability index (HAQ-DI), pain level (visual analog scale - VAS), rate of achieving target uric acid levels. Occurrences of adverse events, and results from electrocardiograms and laboratory tests, will be monitored. DISCUSSION: The findings from this study will offer valuable evidence supporting the efficacy of the QTF in reducing gout flares during ULT.
trial registrationChiCTR20084417 Register on May 16, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.